HQ Team
Editor’s Note: The need for this story arose out of discussions on healthcare access difficulties in the developed world. Horror stories of deliveries gone wrong, difficulties in getting hold of qualified medics, or even tests for the simplest ailments set us thinking of how the Indian healthcare ecosystem seems to be more accessible in comparison, although affordability and equitability is still a big question mark. Keeping that in mind, here we bring you a fresh look at the unprecedented interest of investment conglomerates in India and how hospitals and insurance are slowly being taken over by these PE investment agencies and what it means for the future of Indians seeking healthcare.
June 19, 2026: India’s hospitals are among the hottest investment assets in Asia right now. Global private equity firms, sovereign wealth funds and foreign conglomerates are pouring billions into Indian hospital chains, betting on a young population, rising incomes, and a healthcare system still far too thin for the country’s needs. It is, by any measure, a genuine growth story. But it is also one with a catch. And the catch may be paid for, quite literally, by the patients the system is supposed to serve.
Money pouring in
The numbers tell the story plainly. Global private equity and sovereign funds have invested $15.5 billion , in India’s healthcare sector over the past five years, with hospitals capturing 68% of all that deal flow. Between 2022 and 2024 alone, hospitals drew $4.96 billion in private equity, or 50% of all healthcare deal value in those years.
The names doing the buying are not small. Temasek, Singapore’s sovereign wealth fund, has built a roughly 59% stake in Manipal Hospitals. Blackstone holds about 80% of KIMS Kerala and 73% of Care Hospitals. KKR earned 5.6 times its initial investment on its stake in Max Healthcare. In March 2026, Manipal Health Enterprises filed for an IPO of up to $1.17 billion, with Temasek, TPG and Novo Holdings among the sellers.
Cloudnine chain of hospitals is up for grabs and seven private equity firms are in abiding war for a 25% stake. KKR, TPG Capital, Warburg Pincus, Advent International, CVC Capital Partners, Permira, and domestic fund Kedaara Capital are all competing.
The overall hospital market, currently valued at around $40 billion, is projected to grow at 12% annually over the next three years.
The investment case, at face value, is legitimate. India has only 1.3 hospital beds per 1,000 people — well below the OECD average of 4.3 per 1,000. Around 400 million Indians remain uninsured. Demand is real, the gap is real, and capital has moved in to fill it.
A shift toward premium and specialty
What is less straightforward is where that capital is going inside the healthcare system. Earlier, hospitals in India were more physician-driven, with doctors expanding their practice to some beds, which eventually grew to mid-level hospitals with some private and bank funding. Multi-speciality hospitals came in a little later with private and public investments. Parallelly, government-run hospitals have always been a part of the equation, with teaching hospitals figuring prominently. Now, private equity firms are increasingly shifting focus from general multi-specialty hospitals toward high-return single-speciality verticals where procedures are complex, margins are higher, and patients have fewer alternatives.
The EY-Parthenon consulting group has noted a “sustained shift toward high-acuity specialties such as oncology, cardiology and neurology” across the sector. These are areas where patients are unlikely to shop around or defer treatment. That makes them attractive to investors and expensive for patients in roughly equal measure.
As of 2023, healthcare costs pushed 8 to 9 per cent of all Indian households below the poverty line. A 2024 meta-analysis found that 30% of Indian households face catastrophic health expenditure — five percentage points above the government’s own 2025 policy target of 25%.
It is worth being precise here, because the picture is more complicated than it might seem. India’s out-of-pocket health expenditure as a share of total health spending has actually fallen significantly from over 64% in 2013-14 to around 39.4% by 2021-22, according to the government’s own National Health Accounts data. That is genuine progress. The government increased public health spending from 1.2% of GDP in 2014 toward a target of 2.5% of GDP.
But the absolute costs of hospitalization have continued to rise, even as the share of health spending that comes out of patients’ pockets has declined. And with nearly half of all medical costs still borne directly by households, India sits among the worst performers globally on this indicator. The direction is improving; the level remains a crisis for the poor.
The Ayushman Bharat gap
The government’s answer to this is Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (AB-PMJAY), the world’s largest publicly funded health insurance scheme, which promises up to ₹5 lakh in annual hospitalisation cover for families below the poverty line. In conception, it is an ambitious and necessary intervention. In execution, it is running into serious structural problems.
The most visible flashpoint came in August 2025, when 650 of the 1,300 private hospitals empanelled with AB-PMJAY in Haryana suspended services to scheme patients in protest over ₹490 crore ($59 million) in unpaid reimbursements, dues that were meant to be settled within 15 days but had been outstanding for months. It was not the first time: the same hospitals had threatened suspension in January 2025 over ₹400 crore in pending payments.
The structural tension here is significant. AB-PMJAY relies on private hospitals to deliver care to the poor, but the reimbursement rates the scheme pays are often below what private hospitals, especially PE-backed ones optimized for margin, consider financially viable for routine procedures.
India’s current allocation to AB-PMJAY is barely 0.075% of GDP, compared to Thailand’s 3.2% of GDP on its equivalent universal coverage scheme.
As of February 2026, only 16,746 private hospitals are empanelled under AB-PMJAY out of a total of 44,100 private hospitals in India. In Assam, 354 total providers amount to one hospital for every 100,000 eligible people.
The structural contradiction
The collision between PE-driven consolidation and public health objectives is not theoretical; it is baked into the incentive structure. Private equity funds operate on return timelines of five to seven years. They acquire hospital assets, expand into high-margin specialities, drive operational efficiency, and exit at a multiple. This model is not inherently villainous, and it has genuinely improved technology, infrastructure and management quality at many facilities.
But it is structurally poorly suited to operating low-margin, high-volume public health delivery at scale. PE-backed entities overlook less profitable but essential services, such as primary care, obstetric services in rural settings, and chronic disease management for lower-income populations. These do not generate the returns that justify large-ticket PE investment.
There is also a longer-term risk of what economists call “market segmentation”, where premium hospitals serve insured, urban, upper-middle-class patients, while an underfunded public system absorbs everyone else. The doctor-to-population ratio in rural India already stands at 1 per 2,000 people, double the WHO-recommended ratio. If investment continues to concentrate in urban tertiary care, that gap will widen.
The picture is not static, and it is not entirely gloomy. Several PE firms are investing in Tier 2 and Tier 3 city expansion, which genuinely adds capacity in underserved markets. One peer-reviewed study published in 2025 found that private hospitals operating under the AB-PMJAY model at the district level in Tier 2 and Tier 3 cities can operate profitably while improving access, suggesting the financial model is viable with the right operational approach.
But for the government’s universal health ambitions to survive the PE investment wave, three things need to happen: reimbursement rates under AB-PMJAY need to be competitive and paid on time; public health spending needs to actually reach the 2.5% of GDP target it has missed for years; and regulatory frameworks governing PE ownership of hospitals need to include enforceable access mandates, not just ownership disclosures.
Without these, India risks a two-tier system not by accident but by design; world-class care for those who can pay, and a chronically underfinanced public system for everyone else. The investment is real. The question is who it is ultimately investing in.
